Linked Data API

Show Search Form

Search Results

1686774
registered interest true remove filter
date less than 2024-02-01more like thisremove minimum value filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Genomics: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment she has made of the availability of genomic testing. more like this
tabling member constituency Carshalton and Wallington remove filter
tabling member printed
Elliot Colburn more like this
uin 12685 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-02-09more like thismore than 2024-02-09
answer text <p>The National Genomic Test Directory defines which genomic tests must be delivered by the NHS Genomic Laboratory Hubs in England, as well as who is eligible for genomic testing. The directory currently covers testing for over 3,200 rare diseases and over 200 cancer clinical indications. NHS England regularly updates the directory, through a robust and evidence-based test evaluation process, to keep pace with scientific and technological advances, and to ensure that genomic testing is available for all patients for whom it would be of clinical benefit. Testing is available for all eligible patients across England.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-09T10:40:07.617Zmore like thismore than 2024-02-09T10:40:07.617Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4775
label Biography information for Elliot Colburn more like this
1686775
registered interest true remove filter
date less than 2024-02-01more like thisremove minimum value filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Genomics: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will take steps to ensure future NHS genomic testing publications include data on access to different cancer tests based on an individual's (a) ethnicity, (b) socioeconomic status and (c) type of cancer test. more like this
tabling member constituency Carshalton and Wallington remove filter
tabling member printed
Elliot Colburn more like this
uin 12686 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-02-08more like thismore than 2024-02-08
answer text <p>National Health Service genomic testing activity data, collected from all seven NHS Genomic Laboratory Hubs, is available on the NHS England website. NHS England will continue to publish this data on a quarterly basis. The published data indicates the total volume of genomic testing activity completed per month, broken down into cancer and rare and inherited disease. The cancer data is further separated into nine different categories of cancer. NHS England is looking into separating this further if there are other specific categories of cancer test type which would be of interest. The published data does not currently include data broken down by ethnicity or socioeconomic status, but NHS England’s ambition is to improve and expand future publications of the data, which may include areas relating to health inequalities.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-08T15:27:18.123Zmore like thismore than 2024-02-08T15:27:18.123Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4775
label Biography information for Elliot Colburn more like this
1686776
registered interest true remove filter
date less than 2024-02-01more like thisremove minimum value filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will make an assessment of the implications for her policies of variations in access to genetic and genomic testing for cancer through the NHS Genomics Medicine Service; and what steps her Department is taking to reduce these variations. more like this
tabling member constituency Carshalton and Wallington remove filter
tabling member printed
Elliot Colburn more like this
uin 12687 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-02-08more like thismore than 2024-02-08
answer text <p>The seven NHS Genomic Medicine Service Alliances raise awareness of genomics among healthcare professionals and support delivery of equitable access to genomic testing, clinical genetics, and genomic counselling services. NHS England has also established the NHS Genomics Ethics, Equity and Legal Advisory Group to ensure that the NHS Genomic Medicine Service (NHS GMS) provides equitable access to all patients. The group will identify and review appropriate datasets to inform health inequalities analysis of the NHS GMS, and identify actions to address inequalities.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-08T15:44:36.417Zmore like thismore than 2024-02-08T15:44:36.417Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4775
label Biography information for Elliot Colburn more like this
1686779
registered interest true remove filter
date less than 2024-02-01more like thisremove minimum value filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will make an assessment of the impact of trends in average waiting times for biomarker and genomic testing on waiting times for cancer treatment. more like this
tabling member constituency Carshalton and Wallington remove filter
tabling member printed
Elliot Colburn more like this
uin 12690 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-02-08more like thismore than 2024-02-08
answer text <p>NHS England has implemented capturing of Patient Level Contract Monitoring data across the National Health Service Genomic Laboratory Hubs (GLHs) to facilitate a national approach to reporting and validating activity data and turnaround times. This will enable NHS England to understand activity volumes, detect any backlogs, and institute recovery. NHS England undertakes a quarterly assurance process with each of the NHS GLHs to monitor improvements in turnaround times to ensure these are being met in every region and for all patients.</p><p>NHS England is also undertaking a programme of work alongside clinical experts, including the Medical Royal Colleges, to establish clinically relevant cancer turnaround times across diagnosis, prognosis, treatment determining clinical use cases and optimising cancer pathways to ensure genomic test results are provided in a clinically relevant timeframe.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-08T15:33:11.8Zmore like thismore than 2024-02-08T15:33:11.8Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4775
label Biography information for Elliot Colburn more like this